Drug intelligence / Profile preview

BAY1003803

Development stage: Phase 1
Lead developer: Bayer
Modality: Small Molecules
Administration: Topical

Overview

**BAY1003803** is a Bayer-developed, lipophilic nonsteroidal selective glucocorticoid receptor agonist intended for topical treatment of plaque psoriasis. It was formulated as topical creams and ointment to provide local anti-inflammatory glucocorticoid-receptor activity in psoriatic skin while limiting systemic corticosteroid-related effects. Clinical development included Phase 1 dermal pharmacokinetic, tolerability, and psoriasis plaque-test studies, but the program was discontinued because efficacy in the parallel psoriasis plaque-test program was inadequate.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on BAY1003803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY1003803.

Explore the full profile